PMEF
ABCL icon

Point72 Middle East FZE’s AbCellera Biologics ABCL Stock Holding History

Point72 Middle East FZE’s Portfolio ABCL Stock Details ABCL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-4,704
Closed -$30.4K – 1393
2023
Q2 		$30.4K Buy
+4,704
New +$32.1K ﹤0.01% 1348
2023
Q1 		– Sell
-15,031
Closed -$152K – 1572
2022
Q4 		$152K Buy
+15,031
New +$174K 0.01% 1143

Other funds holding ABCL

Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
VOYA Investment Management
VOYA Investment Management Atlanta, Georgia $116B AUM 61.47% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
CS
Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
ACH
ArrowMark Colorado Holdings Denver, Colorado $2.4B AUM 42.85% 1-Year Est. Return
FFVM
Founders Fund VII Management San Francisco, California $2.03M AUM 72.34% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return

Point72 Middle East FZE's ABCL Position: Q3 2023 in Review

Point72 Middle East FZE sold out of AbCellera Biologics (ABCL) in Q3 2023, closing a stake of 4,704 shares — an estimated $30.4K sold.

Point72 Middle East FZE first reported a position in ABCL in Q4 2022 and held it in 2 quarters. The position peaked at $152K in Q4 2022. 138 funds tracked by Wall St. Rank hold ABCL as of Q3 2023.

  • Point72 Middle East FZE reported no remaining AbCellera Biologics position as of Q3 2023 after selling out during the quarter.
  • Point72 Middle East FZE sold 4,704 AbCellera Biologics shares in Q3 2023, an estimated $30.4K.
  • Point72 Middle East FZE first reported a position in AbCellera Biologics in Q4 2022 and held it in 2 quarters.
  • Point72 Middle East FZE's AbCellera Biologics position peaked at $152K in Q4 2022.
  • 138 funds tracked by Wall St. Rank held AbCellera Biologics as of Q3 2023.

Based on Point72 Middle East FZE's 13F filing for Q3 2023, filed 14 Nov 2023.